Elevance Health, Inc. with ticker code (ELV) have now 15 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $629.00 and $533.00 suggesting an average analyst share price target price of $572.87. (at the time of writing). Now with the previous closing price of $506.11 this indicates there is a potential upside of 13.2%. There is a 50 day moving average of $481.04 while the 200 day moving average is $461.80. The total market capitalization for the company now stands at 119.55B. The stock price for the company is currently $508.83 USD
The potential market cap would be $135,324,350,947 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 20.16, revenue per share of $721.74 and a 5.71% return on assets.
Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefit, CarelonRx, Carelon Services, and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to individual, employer group risk-based, employer group fee-based, BlueCard, Medicare, Medicaid and federal employees health benefits (FEHB) program members. The CarelonRx segment includes its pharmacy business. CarelonRx markets and offers pharmacy services to affiliated health plan customers, as well as to external customers outside of the health plans. Carelon Services offers a broad array of healthcare-related services and capabilities to internal and external customers including integrated care delivery, behavioral health, palliative care, utilization management, payment integrity services and subrogation services, as well as health and wellness programs.
